Clinical Trial Registry Policy Will Be Flexible For Phase II, Journal Editors Say
Executive Summary
Medical journal editors will apply a case-by-case analysis in determining whether to publish data from Phase II studies that have not been listed in public clinical trial registries, the International Committee of Medical Journal Editors said as the July 1 deadline for trial registration approaches
You may also be interested in...
Medical Journals Need Taste Of Their Own Medicine, FDA’s Gottlieb Says
Medical journals need to take measures to expedite providing up-to-date information to physicians, FDA Deputy Commissioner for Scientific & Regulatory Affairs Scott Gottlieb said
Medical Journals Need Taste Of Their Own Medicine, FDA’s Gottlieb Says
Medical journals need to take measures to expedite providing up-to-date information to physicians, FDA Deputy Commissioner for Scientific & Regulatory Affairs Scott Gottlieb said
NEJM Editorial Demands For More Data In Trial Registry Draw Industry Flak
Pfizer and other drug makers are rebuffing criticism from the New England Journal of Medicine that they failed to participate fully in HHS' ongoing initiative to spur registration of clinical trials